The 21 references in paper A. Erlikh D., А. Эрлих Д. (2018) “ФОНДАПАРИНУКС ПРИ ОСТРОМ КОРОНАРНОМ СИНДРОМЕ БЕЗ ПОДЪЕМОВ СЕГМЕНТА ST – ОБОСНОВАНИЕ ДЛЯ ИСПОЛЬЗОВАНИЯ И РЕАЛЬНАЯ КЛИНИЧЕСКАЯ ПРАКТИКА // FONDAPARINUX IN ACUTE CORONARY SYNDROME WITHOUT ST SEGMENT ELEVATION – JUSTIFICATION FOR USING AND REAL CLINICAL PRACTICE” / spz:neicon:aterotromboz:y:2018:i:1:p:26-32

1
Ibanez B, James, S, Agewall S et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC) European Heart Journal, ehx393. https://doi.org / 10.1093 / eurheartj / ehx393.
(check this in PDF content)
2
Roffi M, Patrono C, Collet J-P et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). European Heart Journal, 2016 January 14, 37 (Issue 3): 267–315.
(check this in PDF content)
3
Интернет-ресурс РЛС. / Internet-resource Register of Medicinal Products of Russia. https://www.rlsnet.ru / mnn_ index_id_3221.htm.
(check this in PDF content)
4
Cheng JW. Fondaparinux: a new antithrombotic agent. Clin Ther, 2002 Nov, 24 (11): 1757–1769.
(check this in PDF content)
5
Tran AH, Lee G. Fondaparinux for prevention of venous thromboembolism in major orthopedic surgery. Ann Pharmacother, 2003 Nov, 37 (11): 1632–1643.
(check this in PDF content)
6
Murphy SA et al. Efficacy and safety of the low-molecular weight heparin enoxaparin compared with unfractionated heparin across the acute coronary syndrome spectrum: a meta-analysis. Eur Heart J, 2007, 28 (17): 2077–2086.
(check this in PDF content)
7
Turpie AG, Bauer KA, Eriksson BI, Lassen MR. Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: a meta-analysis of 4 randomized double-blind studies. Arch Intern Med, 2002, 162 (16): 1833–1840.
(check this in PDF content)
8
Buller HR, Davidson BL, Decousus H et al. Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial. Ann Intern Med, 2004, 140 (11): 867–873.
(check this in PDF content)
9
Buller HR, Davidson BL, Decousus H et al. Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism. N Engl J Med, 2003, 349 (18): 1695–1702.
(check this in PDF content)
10
Mehta SR, Steg PG, Granger CB et al. Randomized, blinded trial comparing fondaparinux with unfractionated heparin in patients undergoing contemporary percutaneous coronary intervention: Arixtra Study in Percutaneous Coronary Intervention: a Randomized Evaluation (ASPIRE) Pilot Trial. Circulation, 2005, 111 (11): 1390–1397.
(check this in PDF content)
11
Simoons ML, Bobbink IW, Boland J et al. A dose-finding study of fondaparinux in patients with non-ST-segment elevation acute coronary syndromes: the Pentasaccharide in Unstable Angina (PENTUA) Study. J Am Coll Cardiol, 43 (12): 2183–2190.
(check this in PDF content)
12
Yusuf S, Mehta SR, Chrolavicius S et al. Comparison of fondaparinux and enoxaparin in acute coronary syndromes. N Engl J Med, 2006, 354 (14): 1464–1476.
(check this in PDF content)
13
Jernberg T, Szummer K. Real-world registry study confirms fondaparinux over low-molecular-weight heparin for NSTEMI. EMJ Cardiol, 2015, 2: 89–93.
(check this in PDF content)
14
Эрлих А. Д., Грацианский Н. А. от имени участников регистра «РЕКОРД». Регистр острых коронарных синдромов «РЕКОРД». Характеристика больных и лечение до выписки из стационара. Кардиология, 2009, 7–8: 4–12. / Erlikh AD, Gratsiansky NA on behalf of the participants of the RECORD register. RECORD Acute Coronary Syndromes Register. Characteristics of patients and treatment before discharge from the hospital. Kardiologiya, 2009, 7–8: 4–12.
(check this in PDF content)
15
Эрлих А. Д., Харченко М. С., Барбараш О. Л., Кашталап В. В., Зыков М. В., Печерина Т. Б., Шевченко И. И., Исламов Р. Р., Космачёва Е. Д., Круберг Л. К., Позднякова О. А., Горошко Н. Г., Марков В. А., Сыркина А. Г., Белокопытова Н. В., Горбунов В. В., Гагаркина Л. С., Калинкина Т. В., Зайцева О. Д., Лукьянов С. А., Тагирова Д. Р., Провоторов В. М., Грацианский Н. А. Степень приверженности к выполнению руководств по лечению острого коронарного синдрома в клинической практике российских стационаров и исходы в период госпитализации (данные регистра «РЕКОРД-2»). Кардиология, 2013, 1: 14–22. Erlich AD, Kharchenko MS, Barbarash OL, Kashtalap VV, Zykov MV, Pecherina TB, Shevchenko II, Islamov RR, Kosmacheva ED, Kruberg LK, Pozdnyakova OA, Goroshko NG, Markov VA, Syrkina AG, Belokopy
(check this in PDF content)
16
Эрлих А. Д., Грацианский Н. А. от имени всех участников регистров «РЕКОРД» и «РЕКОРД-2». Острый коронарный синдром без подъемов сегмента ST в практике российских стационаров: сравнительные данные регистров «РЕКОРД-2» и «РЕКОРД». Кардиология, 2012, 10: 9–14. / Erlikh AD, Gratsiansky NA on behalf of all participants of RECORD and RECORD-2 registers. Acute coronary syndrome without ST segment elevations in the practice of Russian hospitals: comparative data of RECORD and RECORD-2 registers. Kardiologiya, 2012, 10: 9–14.
(check this in PDF content)
17
Эрлих А. Д., Грацианский Н. А. от имени участников регистра «РЕКОРД-3». Российский регистр острого коронарного синдрома «РЕКОРД-3». Характеристика пациентов и лечение до выписки из стационара. Кардиология, 2016, 4: 16–24. / Erlick AD, Gratsiansky NA on behalf of the participants of RECORD-3 register. RECORD-3 Russian acute coronary syndrome registry. Characteristics of patients and treatment before discharge from the hospital. Kardiologiya, 2016, 4: 16–24.
(check this in PDF content)
18
Matos Soeiro А, Melo de Barros e Silva PG, de Castro Roque EA et al. Fondaparinux versus Enoxaparin – Which is the Best Anticoagulant for Acute Coronary Syndrome? – Brazilian Registry Data. Arq Bras Cardiol, 2016, 107 (3): 239–244.
(check this in PDF content)
19
Pepe C, Machado M, Olimpio A, Ramos R. Cost-effectiveness of fondaparinux in patients with acute coronary syndrome without ST-segment elevation. Arq Bras Cardiol, 2012, 99 (1): 613–622.
(check this in PDF content)
20
Ross Terres JA, Lozano-Ortega G, Kendall R, Sculpher MJ. Cost-effectiveness of fondaparinux versus enoxaparin in non-ST-elevation acute coronary syndrome in Canada (OASIS-5) BMC Cardiovasc Disord, 2015, 15 (1): 180–180.
(check this in PDF content)
21
Permsuwan U, Chaiyakunapruk N, Nathisuwan S, Sukonthasarn A. Cost-Effectiveness Analysis of Fondaparinux vs Enoxaparin in Non-ST Elevation Acute Coronary Syndrome in Thailand. Heart Lung Circ, 2015 Sep, 24 (9): 860-868.
(check this in PDF content)